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Ebola Virus 
• Member of the filoviridae family of viruses, first discovered in 1976 in 
the Ebola river (Zaire, now, Democratic Republic of Congo) 
 
• Hemorrhagic fever and deadly disease caused by infection with one 
of the Ebola virus strains (Human: Zaire, Sudan, Ivory Coast, 
Bundibugyo; non-human primates: Reston) 
 
• Animal-borne virus, with fruit bats as most likely reservoir 
− Natural reservoir host not yet identified 
 
• Transmission by direct contact (through broken skin or mucous 
membranes) with blood or body fluids of infected individual or 
contaminated objects, and infected fruit bats or primates 
Ebola Virus Disease: Clinical Features 
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• Acute onset; typically 8 -10 days after exposure (range 2 – 21 days) 
 
• Nonspecific early clinical signs and symptoms 
− Initial  
 Fever, chills, myalgia, malaise, anorexia 
− After 5 days, GI symptoms:  
 Nausea, vomiting, watery diarrhea, abdominal pain 
− Hemorrhagic symptoms in 18% cases 
 
• Symptoms progress to: 
− Hemorrhagic disease 
− Hypovolemic shock, multi-organ failure 
− Death (case fatality rate >50%) 
2014 – 2016 Ebola Virus Outbreak 
• First case in Guinea March 2014 and peaked in Aug–Oct ’14 
− WHO declaration of Public Health Emergency on International 
Concern (PHEIC) on August 8th  
 
• Zaire ebolavirus species  
 
• Cumulatively 28,000+ cases and 11,000+ deaths by January 
2016 
− > 10 times more cases during the current epidemic than in all previous 
outbreaks combined 
− Impacted: Guinea, Liberia, Sierra Leone 
 A few cases reported in Nigeria, Mali, Senegal, Spain, US, UK, and Italy 
 
• WHO declares outbreak over on January 14th, 2016 
− New cases have been detected in Sierra Leone since 
 http://who.int/mediacentre/news/releases/2016/eb
ola-zero-liberia/en/ 
Ebola Clinical Candidates During 2014 – 2016 
Western African Outbreak 
Taken from WHO Report on Ebola R&D Landscape of Official Candidates and Trials (October 2015) 
Development History for Merck’s Ebola 
Vaccine Candidate 
• Application of the rVSV technology and initial development  of the candidate Ebola vaccine was 
accomplished by Public Health Agency of Canada (PHAC) 
 
• PHAC licensed the filovirus vaccine technology to NewLink Genetics to further development and 
initiate clinical development 
 
• The initial PHAC clinical lot was manufactured in 2013 by the German CMO and utilized in most 
clinical trials 
• NewLink Genetics filed IND and started Phase I trials (3 sites) and oversaw the clinical development 
• Funding to support development and clinical lots completed by multiple partners 
•  BARDA, DTRA, Wellcome Trust, NIH, NIAID and WHO 
• PHAC lot utilized to support Phase II/III in West Africa (Liberia, Guinea, Sierra Leone)  
• NewLink Genetics continued to work with IDT for additional clinical lots and process development 
 
• Towards the end of 2014, Merck and NewLink Genetics Corp. entered into an exclusive worldwide 
license agreement  
• Merck assumed responsibility to research, develop, manufacture, and distribute the investigational Ebola vaccine 
candidate (rVSV- ∆G-ZEBOV-GP) and other filovirus based vaccines based on rVSV technology 
 
• Merck, NewLink Genetics and a global network of partners are collaborating in unprecedented ways 
with the singular focus on speeding the research, development and deployment of a well-tolerated 
and effective Ebola vaccine 
Composition of Merck’s Ebola Vaccine 
Candidate (rVSV- ∆G-ZEBOV-GP) 
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Vector = live attenuated recombinant vesicular stomatitis 
virus (rVSV) 
− Antigen = Zaire Ebola virus (ZEBOV) glycoprotein (GP) 
 VSV G (envelope) GP replaced with Ebola-Zaire envelope GP 
 Eliminates VSV GP toxicity and changes host range 
• rVSV-∆G-ZEBOV-GP is replication-competent, displaying ZEBOV GP in native 
conformation on the surface of the VSV particle 
• Preclinical and clinical data suggest that a single dose of V920 is sufficient for inducing 
rapid, protective responses   
• Consistent with utility in resource poor environments and in an outbreak situation 
Lancet publication of Interim 
Analysis on July 31st 2015 
• First evidence of efficacy in 
human subjects for any Ebola 
vaccine 
 
• No EVD cases in either 
immediate or delayed arm from 
Day 6 post dose onward 
 
• Study expanded into Sierra 
Leone with all additional 
subjects vaccinated upon 
enrollment (no delayed arm) 
 
• Enrolling adolescents and 
children > 6 years old 
WHO Guinea Ring Vaccination Trial: Interim 
Analysis Efficacy Results 
Merck’s Approach to Address Potential 
Vaccine Needs and Vaccine Availability 
• Move monovalent frozen product forward for licensure as efficiently as possible 
− Complete clinical development to produce required safety database, demonstrate evidence of clinical 
benefit, and manufacturing consistency 
− Prepare commercial manufacturing facility and execute on manufacturing scale-up and PPQ activities 
 
• Collaborate with current dose owners and stakeholders to align on best use of existing 
doses of vaccine (~150 – 170K currently exist) 
− Through expanded ring vaccination trials, new/expanded trials for at-risk US-based and ex-US populations, 
trials in special populations etc.  
 
• Ramp up Merck manufacturing capabilities (Pilot Plant) to produce additional doses that 
could be deployed in the case of expanded or new outbreak (not commercial doses; only 
for clinical trials or emergency use) 
− Ethical obligation to ensure vaccine available in the event of another epidemic 
− Merck now has successfully manufactured and stored ~120K doses and ~500K dose equivalents 
 
• Kick off early development of thermostable product(s) to protect against key Filoviruses 
Typical Timeline for Vaccine Development 
10 to 20 Years 
Standard timeline to develop a vaccine. 
2024+ 2014 
Merck’s Vaccine Milestones and Accelerated 
Timeline to Develop the Ebola Vaccine 
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SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB 
2015 2014 
II/III I III III 
      
2016 
17 Aug 15  
Initiation 
of Merck Phase III 
Safety and Lot 
Consistency Study 
(P012) 
in US/EU/Canada 
31 July 15  
Phase III ring 
vaccination trial 
interim analysis 
results 
demonstrate 
vaccine efficacy 
 
23 Aug 15  
Siting 
Decision and  
Process  
Development 
Kicked-off 
Internally 
Sep 15  
CAPEX 
Scoping 
Project 
Initiated at 
Manufacturing 
Site 
Jan/Feb 16 
Manufacture 
of  DP Lots 
for EMU 
within Merck 
Facility 
Dec 15 
Manufacture 
of BDS Lots 
for EMU at 
Anticipated 
Commercial 
Scale 
Over 18,000 volunteers vaccinated to date 
Nov 15  
BARDA 
Lots F/F 
@ Merck 
13 Oct 2014 
Start of  
Phase I trials 
rVSV-ZEBOV-
GP 
25 Jan 
2015 
Dose 
selection 
decision for 
efficacy trials 
2 Feb 2015  
Initiation of  
NIH-Liberia 
PREVAIL  
Phase II/III 
study 
09 April 2015  
Initiation 
of CDC 
STRIVE  
Phase III trial  
in Sierra Leone  
23 Mar 2015  
Initiation of 
WHO  
Phase III  
study in Guinea 
22 Dec 2015 
WHO agrees to 
review an 
Emergency Use 
Assessment and 
Listing 
submission 
Process Development 
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Scope of Process Development 
• Obtain data to support BLA filing 
− Generate necessary lab-scale development data to support critical ranges 
− Generate comparison data of clinical and commercial processes 
 
• Develop commercial scale-up process and move from existing clinical process 
− Show comparability between clinical and expected commercial process 
− Minimize changes to existing process to shorten timelines and accelerate program  
− Utilize knowledge gained through EMU manufacturing for scale-up development 
 
 
• QbD Risk based approach to parameter studies 
− Gain process knowledge and explore processing surface to ensure process parameters are in a stable 
zone 
− Team not investigating all areas of process, but rather focused on key areas 
 Expedites process development and increases team’s efficiency in delivering a commercial process 
− Utilizing clinical scale targets 
 Only adjusting unit operations necessary to ensure a robust manufacturing process is achieved (i.e. 
TFF) 
 
 
Vaccine Process Flow 
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Cell Seeding 
Cell Passage 
Virus Infection 
Virus Harvest 
Enzyme Treatment 
Virus Purification and 
Concentration 
Freeze at < -60ºC 
Formulation (Thaw, Dilute, 
Blend) 
Fill Vials 
Stopper/Cap 
Inspect 
Label 
Package 
Freeze at < -60ºC 
Ship 
• DS and DP is stored 
and kept at < -60C 
 
• Preliminary data 
indicates DP stable at      
2-8ºC for 3 – 4 weeks 
 
• Next generation 
vaccine to explore a 
more thermostable 
formulation 
Vaccine Path to PPQ  (Upstream and 
Downstream Drug Substance Development) 
• Upstream Development 
− MOI 
− Plant density 
− Day of Infection 
− Harvest Time 
− PBS Rinse 
− Medium Age 
Process 
Development 
Kicked Off 
[Aug2015] 
Reviewed and 
scored prelim 
FMEA 
Identified key 
experiments 
to support 
PPQ ranges 
• Downstream Development 
– Depth Filtration Pmax 
Studies 
– Enzyme Rxn 
• DOE 
• Time course studies 
– TFF 
• DOE 
• Impact of Loading 
• Other DS Studies 
– Hold time studies 
• Stock seed 
• HVF 
• CH 
• RVH 
– Investigate  various 
RB sizes 
Impact of MOI and Harvest Time:  
Finalized Response Surface Design 
Factor Levels 
MOI (1 PFU: viable 
cell) 
 
MOIs examined over 
100-fold range 
Harvest Timing (HPI) 
 
 
Examined harvesting 
over multiple days post 
infection 
JMP design including 
replicates and 6 center 
points 
30 conditions 
Replicate experiment  Experiment 1 
Conditions 1-30 
Experiment 2 
Conditions 1-30 Same design used in both 
experiments, replicate to gain 
confidence around results 
Relative Impact of MOI and Relative 
Harvest Time on Potency 
• Proposed operating space highlighted in red box 
• Large operation window for Harvest time and MOI 
• Data  from 3rd & 4th DOE at lower MOI indicates large operating space 
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Comparison of the Expected Merck 
Commercial Process with Clinical Process 
• Data presented are for 
Harvested Viral Fluids 
 
• Lab-scale results (blue 
diamonds) compared to 
clinical process (red 
circles) 
• Arrows indicate lots 
utilized in clinical trials 
 
• Lab-scale and clinical 
processes comparable 
for potency and harvest 
times 
• Development fits well into 
operating space 
Process Comparability:  Clinical / 
Emergency Use /  Commercial Scale 
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• Commercial process is 
comparable to EMU and 
clinical process 
• No significant 
differences in final BDS 
potencies 
 
• Final yields within 
clinical experience 
range 
 
• Blue: CMO Clinical 
• Black: CMO Non-clinical 
• RED: Merck Lots 
Expected Process Parameters  (Comparison 
of Clinical and Commercial Process) 
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Clinical Process 
(CMO) 
Commercial Process  
Harvesting Time  
 
No Expected Changes 
MOI 
Reaction Temperature 
Reaction Time 
Reactor GE Wave Bioreactor 200L SU Jacketed 
Vessel 
Mixing Process Rocking  Bottom Mounted 
Magnetic Stirrer 
• No significant changes across the process expected 
– Goal is to minimize changes, only modify steps necessary for scale-up 
Vaccine Path to PPQ (DP Development) 
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• Impact of shear and mixing on final formulated bulk (FFB) 
 
• Short-term stability studies to investigate the impact of normal manufacturing 
times and temperatures on drug product potency 
− 2-8C 
− TOR 
 
• Impact of freezing and thawing  
 
• BDS dilutability studies to target a final DP potency 
 
• Materials of contact experiments and examination of CCI for the final DP 
image 
− SD and MD vials 
− Examination of different formulation vessels (i.e., SS, Glass, SUT) 
 
• Long-term stability studies for DP stability studies 
 
 
DP Results:  Impact of Vaccine to Shear 
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• DP not impacted by shear 
stress 
• DP was exposed to 180 
turnovers in an 
experimental shear cell 
 
Impact of Freezing Rate of Ebola DP 
Stability 
• Evaluated impact of 
freezing rate on DP 
• Quick freezing in LN2 
blast freezer (15min) 
• Slow freezing in -70C 
freezer (2 & 8hr) 
• 72hr freeze controlled in 
Lyophilization cabinet 
• Mimics expected large 
lot freezing time 
 
• Method of freezing does 
not appear to impact 
potency 
• Allows flexibility for 
manufacturing and 
freeze process 
Impact to Thawing Rate on Ebola DP 
Potency (10D image) 
• Thaw rate impacts DP 
potency in 10D image 
• Single Dose Vial study 
showed similar trend 
 
• Thawing protocol important 
for vaccine  field use 
• Thaw at RT to minimize the 
thaw time  
 
Ebola DP Freeze / Thaw Stability 
• Vaccine appears stable 
through 5 Freeze-thaw 
cycles 
• Flexibility in manufacturing 
for packaging and labelling 
• Vials frozen in -70ºC freezer 
and thawed at room 
temperature 
Dilutability of  Ebola BDS to DP Target 
Potency 
• BDS can be diluted to 
specified DP potency 
• Increased confidence in 
achieving formulation 
and filling targets 
• Examined both clinical 
and commercial 
processes 
Initial Development of Lyophilized 
Formulation for Potential Ebola Next Gen 
Product 
• All formulations examined achieve acceptable cake appearance with non-optimized 
cycle 
 
• Initial formulation development focused on lyophilization yields and accelerated 
stability 
• Utilize accelerated stability to identify lead formulations for long-term stability studies 
Tech Transfer Site Readiness Roadmap 
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Stage 
Gate 4 
Initiation, 
Planning, 
Capital Project, 
Quality System 
Assessment, 
Analytical TT 
Process & Site 
Readiness 
Process 
Performance 
Qualification Lots 
(PPQ) 
Filing 
Preparation, 
Comparability 
Report &  
Pre-launch Audit 
Stage 
Gate 
0 
Stage 
Gate 2 
Stage 
Gate 3 
File Submission,  
Routine 
Manufacturing and   
Stability 
Engineering Lots 
Stage 
Gate 1 
Process 
Simulations 
Stage 
Gate 5 
Program Challenges 
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• Three parallel activities within Merck to drive program forward and inability 
to sequence  
• Develop Scale-up process for Commercial Manufacturing 
• Site and Tech Transfer strategy and CapEx project to ready the facility as soon as possible 
• Process  not fully assessed and design space not understood, required development in-lab to 
fit to facility and better understand process 
• Manufacture Emergency Use Material to Support a Potential Future Zaire Ebola 
Outbreak 
• Ensure doses available prior to licensed product in an emergency / clinical setting 
• Development efforts initiated for next generation vaccine candidate 
• Thermostable lyophilized product 
 
• Different approaches to risk based decision making 
– Team not investigating all areas of process, but rather focused on key areas 
• Expedites process development and increases team’s efficiency in delivering a commercial 
process 
 
 
• Rapidly evolving external environment 
• Aug. 2015: Ebola Outbreak in progress;  Jan. 2016; WHO declares Ebola outbreak over 
• Numerous points to interact with during development for both development and funding 
• WHO, GAVI, BARDA, DTRA, DOD, Wellcome Trust, NewLink/BPS, NIH, NIAID 
Applicability of Strategy Applied for Merck’s 
Ebola Vaccine to Other Programs 
• Examination of changes in scale and bulk process for later stage 
development 
• Changing scale  
• Moving from clinical scale to commercial scale  
• Moving to different platform for production 
• RB process to cell stacks or microcarriers for BDS production 
• Moving from transient transfectants in early stage development to stable clones 
 
• Formulation changes during development 
• Biologics utilizing “platform” formulations in early phase programs and later moving 
to commercial formulation 
• Moving from frozen liquid  formulations to improved refrigerator stable and 
lyophilized formulations as move into Phase II and beyond  
 
• Building strong analytical comparability to minimize clinical 
studies 
 
 
Summary, Conclusions, and Successes 
• Merck committed to move the vaccine forward to licensure as quickly as 
possible and ensure vaccine availability for at-risk populations in advance of 
product licensure 
• Merck has successfully manufactured clinical trial/EMU supplies 
• ~120K doses available and another ~500K dose equivalents 
• Filed necessary EUAL with WHO  
 
• Strong preclinical data, including evidence of protection after single dose 
• Positioned the vaccine to be an important vaccine candidate in response to recent Ebola 
outbreak 
 
 
• Merck has shown ability to scale process from clinical to commercial 
process 
• Comparability assessment underway between processes 
 
 
• Initial efforts underway to examine next generation product 
• Thermostable / lyophilized product 
 
• Merck and NewLink working in collaboration with a large number of partners 
• Regulators, Academia, International Health Agencies, NGOs, US Military, and other US 
and ex-US government agencies have moved the vaccine forward at an unprecedented 
pace 
 
Partnerships and Alliances 
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Public Health Agency  
of Canada (PHAC) 
NewLink Genetics (Bio-Protection 
Systems Corporation) 
Phase I Studies 
̶ Switzerland: University Hospitals of Geneva 
̶ Germany: University Medical Center 
Hamburg/Clinical Trial Center North  
̶ Gabon: Centre de Recherches Medicales de 
Lambarene/University of Tuebingen 
̶ Kenya: Kenya Medical Research Institute  
̶ Marburg Laboratory 
• CCV – Halifax, Canada 
• US Department of Defense  
(WRAIR, JVAP, USAMRIID, DTRA)  
• NIAID/NIH 
• BARDA 
WHO Clinical Consortium/ 
Wellcome Trust 
Phase II/III Studies 
• Liberia: Liberia –  
NIH Partnership (NIAID)  
• Sierra Leone: CDC/ 
Sierra Leone Medical  
School, BARDA  
• Guinea: WHO/Norwegian Institute of Public 
Health//MSF/Health Canada  
 
• US Department of Defense (WRAIR, JVAP, 
USAMRIID, DTRA) 
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Thank You!! 
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V920 Merck’s selection of the NewLink 
rVSVΔG-ZEBOV-GP LVV live 
attenuated candidate was validated 
with extremely positive efficacy results 
The V920 internal Merck team is highly functioning, motivated and dedicated.  They 
have accomplished an extraordinary amount of work with external partners in a 
relatively short time frame. “Best team I’ve ever worked with in my career”  
Popular Science 
QUESTIONS? 
